Dr. Bernard Fisher, the surgeon whose research played a key role in the shift from radical mastectomy to less aggressive procedures for early-stage breast cancers, turns 95 this month. As director of the National Surgical Adjuvant Breast and Bowel Project (NSABP), Dr. Fisher championed the role of the randomized clinical trial. Yet, his career was nearly destroyed by allegations of scientific misconduct regarding falsified data from one of the surgeons in his study. Ultimately, he was exonerated, and resumed his research career which included establishing the role of tamoxifen for lowering breast cancer risk in high-risk women. To read an article on Dr. Fisher written for The Atlantic, click here.